Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

If the whole breast is removed because of breast cancer, several options for breast reconstruction are available. All these options have an increased complication risk if a patient has been or will be treated with radiotherapy. However, only a few high-quality studies addressed patient satisfaction and complication risks, both in terms of timing (prior to or after irradiation) and type of reconstruction (implant or own tissue). As radiotherapy indications expand and more patients desire a reconstruction, this is a progressively relevant issue. Through this nationwide prospective study, the investigators aim to identify the most ideal treatment strategy by comparing different reconstruction options in terms of patient reported outcomes (PROs), toxicity, oncological safety and costs. These results will enable improvement of shared decision-making and cost-effectiveness of breast reconstruction strategies in case of radiotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Patient satisfaction at 1 year (From enrollment to one year follow-up after treatment.)
  • Patient quality of life at 1 year (From enrollment to one year follow-up after treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-22
Completion: 2032-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Janine M. Simons MD PhD
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development, Maastro Clinic, The Netherlands
Contact Information
Study Contact:
Janine M Simons, MD PhD
0031107040521
j.simons@erasmusmc.nl
Simone Schnitzler, MD
0031630899908
s.schnitzler@erasmusmc.nl
Erasmus Medical Center
Interventions
N/A
Study Locations (1 sites)
Erasmus Medical Center, Rotterdam, Netherlands
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Diagnosed with unilateral non-metastatic breast cancer * (to be) Treated with mastectomy and to be treated with adjuvant radiotherapy * Willing and able to provide written informed consent Exclusion Criteria: * History of DCIS or invasive breast cancer * Previous thoracic radiotherapy treatment * History of other malignancies (except for patients with basal or squamous cell skin cancer, in situ carcinoma of the cervix and patients who are disease-free at least 5 years following successful treatment for other malignancies)
Conditions Breast Cancer, Gastric Cancer, Esophagea...
Phase PHASE2
Enrollment 200
Locations 28 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Zanidatamab — Administered by intravenous (IV) infusion

Primary Outcomes

  • Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR (Up to 2.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-14
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Ireland Limited
Contact Information
Study Contact:
Clinical Trial Disclosure & Transparency
215-832-3750
ClinicalTrialDisclosure@JazzPharma.com
Interventions
  • Drug: Zanidatamab — Administered by intravenous (IV) infusion
Study Locations (28 sites)
Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona 86301 United States
Rocky Mountain Cancer Center, Littleton, Colorado 80120 United States
Florida Cancer Specialists - South, Fort Myers, Florida 33901 United States
Florida Cancer Specialists - Lake Nona, Orlando, Florida 32827 United States
Florida Cancer Specialists - North, St. Petersburg, Florida 33705 United States
Florida Cancer Specialists - East, West Palm Beach, Florida 33401 United States
Affiliated Oncologists, Chicago Ridge, Illinois 60415 United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Alliance Cancer Specialists, Horsham, Pennsylvania 19044 United States
Eligibility Criteria
Inclusion Criteria: 1. Is at least 18 years of age inclusive at the time of signing the informed consent 2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required. 3. HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory. 4. All participants must have adequate tumor sample for submission to allow central HER2 testing. 5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Has a life expectancy of at least 3 months, in the opinion of the investigator. 8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met: 1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS. 2. Participants with treated CNS metastases that are no longer symptomatic may be included in the study if they recovered to \< Grade 1 (CTCAE Version 5.0 or higher) or baseline from the acute toxic effect associated with the treatment \> 7 days prior to Cycle 1 Day 1. 3. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention. 9. Adequate organ functions. 10. Females of childbearing potential must have a negative pregnancy test result. 11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control. Exclusion Criteria: 1. Has known or suspected leptomeningeal disease and/or untreated brain metastasis. 2. Has uncontrolled or significant cardiovascular disease 3. Has ongoing toxicity related to prior cancer therapy 4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals. 5. Has known Human Immunodeficiency Virus (HIV) infection. 6. Has active hepatitis B or C infection. 7. Has an active SARS-CoV-2 infection. 8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab. 9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site. 10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study. 11. Prior treatment with HER2-targeted therapy (Cohort 1 only). 12. Has a history of trauma or major surgery 13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1. 14. Received zanidatamab at any time prior to the current study. 15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations. 16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion. 17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy. 18. Prior or concurrent invasive malignancy other than the disease under study, whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.
Conditions Metastatic Invasive Lobular Carcinoma (m...
Phase Not Applicable
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: circulating tumor DNA (ctDNA) — Signatera is based on a custom-designed multiplex polymerase chain reaction (mPCR) assay for each patient, targeting up to 16 mutations found in the patient's tumor during whole exome sequencing (WES) to create a unique tumor mutation signature.

Primary Outcomes

  • Change in ctDNA (Baseline, at 4 weeks, at 8 weeks, at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-12
Completion: 2029-10-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Julia Foldi
Principal Investigators:
  • Julia Foldi, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Lucia Borasso, BA
4126413304
borrlm@upmc.edu
Kelsey Mitch, RN
4126412357
adamikka2@upmc.edu
Lucia Borasso, BA
4126413304
borrlm@upmc.edu
Magee Women's Hospital of UPMC
Interventions
  • Diagnostic Test: circulating tumor DNA (ctDNA) — Signatera is based on a custom-designed multiplex polymerase chain reaction (mPCR) assay for each patient, targeting up to 16 mutations found in the patient's tumor during whole exome sequencing (WES) to create a unique tumor mutation signature.
Study Locations (1 sites)
Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent 2. Patients must have histologically or cytologically confirmed invasive lobular breast cancer that is ER+ (\> 1% staining) and HER2-negative as per ASCO/CAP guidelines with radiographical or clinical evidence of metastatic disease 1. Lobular histology as assessed on either tissue collected from a metastatic lesion or from the patient's primary breast tumor (in case of recurrent metastatic disease) 2. Patients with mixed ductal/lobular (NST/ILC) tumors are eligible to participate (with the ultimate goal to evaluate 20 patients with pure ILC) 3. Patients must have tumor tissue available for whole exome sequencing for Signatera assay design 3. Prior therapies: 1. Patients must not have received any therapy in the metastatic setting 2. Patients could have received adjuvant therapy as indicated for their primary breast cancer 4. Age ≥ 18 years 5. Patients may be pre- or post-menopausal. Exclusion Criteria: 1. Stage I-III breast cancer 2. Lack of lobular histology on tumor tissue biopsy 3. Other active cancer (previously treated cancer with no current evidence of disease is allowed) 4. ctDNA assay development is unattainable due to insufficient tumor tissue or sequencing failure
Conditions Breast Cancer Screening, Artificial Inte...
Phase PHASE4
Enrollment 400000
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI) decision-support tool in real-world U.S. settings and to assess patients' and radiologists' perspectives on AI in medicine. The main question it aims to answer is: Does an FDA-cleared AI decision-support tool for digital tomosynthesis (DBT) improve screening outcomes in real world US clinical settings? This trial will include all interpreting radiologists and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (University of California, Los Angeles (UCLA), University of California, San Diego (UCSD), University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period. All screening mammograms at these facilities will be randomized to either intervention (radiologist assisted by an AI decision support tool) versus usual care (radiologist alone) to see if interpreting these mammograms with the AI tool's assistance improves patient screening outcomes. We are targeting 400,000 screening exams across the participating health systems in this trial.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Single

Interventions / Regimen

  • Device: Artificial intelligence (AI) decision-support tool — The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information). Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system.

Primary Outcomes

  • Cancer detection rate (Cancer diagnosed within 90 days of positive study entry screening mammogram)
  • Recall rate (Through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-15
Completion: 2030-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: University of California, Los Angeles, University of California, San Diego, University of Wisconsin, Madison, Boston Medical Center, Patient-Centered Outcomes Research Institute, University of Washington, California Breast Cancer Research Program, University of Miami, University of California, Davis
Principal Investigators:
  • Joann G Elmore, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
  • Diana Miglioretti, PhD (PRINCIPAL_INVESTIGATOR) - University of California, Davis
Contact Information
Study Contact:
Michelle L'Hommedieu, PhD
(310) 592-9454
mlhommedieu@mednet.ucla.edu
Michelle L'Hommedieu, PhD
(310) 592-9454
mlhommedieu@mednet.ucla.edu
University of California Los Angeles Health System
Hannah S. Milch, MD
University of California Los Angeles Health System
Interventions
  • Device: Artificial intelligence (AI) decision-support tool — The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information). Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system.
Study Locations (6 sites)
University of California Los Angeles Health System, Los Angeles, California 90024 United States
University of California, San Diego, San Diego, California 92093 United States
University of Miami Health System, Miami, Florida 33136 United States
Boston Medical Center, Boston, Massachusetts 02118 United States
University of Washington Health System, Seattle, Washington 98195 United States
University of Wisconsin-Madison, Madison, Wisconsin 53706 United States
Eligibility Criteria
This trial will include all radiologists interpreting screening mammography and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (UCLA, UC San Diego, University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period. Individuals must meet the following eligiblity criteria. Inclusion Criteria: 1. Be at least 18 years of age or older 2. Receive a screening mammogram at one of the participating breast imaging facilities OR be a radiologist who interprets screening mammograms at one of the participating breast imaging facilities. Exclusion Criteria: 1\. Patients who have opted out of all research at the health system
Conditions HER2-positive Breast Cancer
Phase Not Applicable
Enrollment 9000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify constitutional genetic factors associated with histological response, resistance or sensibility to treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 9000 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclusion in the study. Patients will be treated and followed according to the standards of their treating center. They will be followed every six months for five years.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Blood sample for genetic analysis — Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study

Primary Outcomes

  • Pathologic Complete Response (pCR) (at the end of enrollment (3 years))
  • Disease Free Survival (DFS) (At the end of the study (8 years))
  • Overall Survival (OS) (At the end of the study (8 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-12-15
Completion: 2033-12-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 9000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Paul Strauss
Contact Information
Study Contact:
Valérie SARTORI
368767223
v.sartori@icans.eu
Manon VOEGELIN, PhD
368767360
promotion-rc@icans.eu
Valérie SARTORI
368767223
v.sartori@icans.eu
Institut de cancérologie Strasbourg Europe
Interventions
  • Other: Blood sample for genetic analysis — Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
Study Locations (1 sites)
Institut de cancérologie Strasbourg Europe, Strasbourg, 67033 France
Eligibility Criteria
For inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria: Inclusion Criteria: * Age ≥ 18 years * Histological diagnosis of breast adenocarcinoma. Non-metastatic and operable. * Current or prior treatment with one therapy targeting HER2 in adjuvant or neoadjuvant phase for the current breast cancer * Given written informed consent Exclusion Criteria: * Patients not able to comply to the protocol assessments for geographic, social or psychological reasons * Patients placed under judicial protection, guardianship, or supervision * History of cancer in the 5 years preceding anti-HER2 therapy initiation * Concomitant cancer (except for an other non metastatic cancer treated only with surgery) Note : Patients are eligible at any time of the follow-up if the adjuvant or neoadjuvant chemotherapy started after 01/01/2019. Patients treated with trastuzumab, pertuzumab, neratinib or T-DM1 in a clinical trial are eligible in the SIGHER study.
Conditions Breast Cancer
Phase PHASE3
Enrollment 3960
Locations 1261 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ovarian Function Suppression + Aromatase Inhibitor — Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
  • Drug: Adjuvant Chemotherapy + Ovarian Function Suppression — Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.

Primary Outcomes

  • Invasive breast cancer-free survival (IBCFS) (Time from randomization for duration of trial, 11 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-10-18
Completion: 2034-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 3960 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Director Regulatory Affairs
412-339-5300
langerj@nrgoncology.org
Norman Wolmark, MD
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org
Anchorage Associates in Radiation Medicine
Interventions
  • Drug: Ovarian Function Suppression + Aromatase Inhibitor — Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
  • Drug: Adjuvant Chemotherapy + Ovarian Function Suppression — Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Study Locations (1261 sites)
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States
Anchorage Associates in Radiation Medicine, Anchorage, Alaska 98508 United States
Anchorage Radiation Therapy Center, Anchorage, Alaska 99504 United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska 99508 United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska 99508 United States
Alaska Women's Cancer Care, Anchorage, Alaska 99508 United States
Anchorage Oncology Centre, Anchorage, Alaska 99508 United States
Katmai Oncology Group, Anchorage, Alaska 99508 United States
Providence Alaska Medical Center, Anchorage, Alaska 99508 United States
Fairbanks Memorial Hospital, Fairbanks, Alaska 99701 United States
Eligibility Criteria
Inclusion Criteria: * A patient cannot be considered eligible for this study unless ALL of the following conditions are met. * The patient or a legally authorized representative must provide study-specific informed consent prior to pre-entry and, for patients treated in the U.S., authorization permitting release of personal health information. * Female patients must be greater than or equal to 18 years of age. * Patients must be premenopausal (evidence of functioning ovaries) at the time of pre-entry. For study purposes, premenopausal is defined as: * Age 50 years or under with spontaneous menses within 12 months; or * Age greater than 50-60 years with spontaneous menses within 12 months plus follicle-stimulating hormone (FSH) and estradiol levels in the premenopausal range; or * Patients with amenorrhea due to IUD or prior uterine ablation must have FSH and estradiol levels in the premenopausal range; or * Patients with prior hysterectomy must have FSH and estradiol levels in the premenopausal range. * The patient must have an ECOG performance status of less than or equal to 2 (or Karnofsky greater than or equal to 60%). * Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. * Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. * Patient may have undergone a total mastectomy, skin-sparing mastectomy, nipple-sparing mastectomy, or a lumpectomy. * For patients who undergo a lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS (ductal carcinoma in situ) with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. Positive posterior margin is allowed if surgeon deems no further resection possible. (Patients with margins positive for LCIS (lobular carcinoma in situ) are eligible without additional resection.) * For patients who undergo mastectomy, the margins must be free of residual gross tumor. (Patients with microscopic positive margins are eligible if post-mastectomy RT (radiation therapy) of the chest wall will be administered.) * Patient must have undergone axillary staging with sentinel node biopsy (SNB), targeted axillary dissection (TAD), or axillary lymph node dissection (ALND). * The following staging criteria must be met postoperatively according to AJCC 8th edition criteria: * By pathologic evaluation, primary tumor must be pT1-3. (If N0, must be T1c or higher.) * By pathologic evaluation, ipsilateral nodes must be pN0 or pN1 (pN1mi, pN1a, pN1b, pN1c). * Patients with positive isolated tumor cells (ITCs) in axillary nodes will be considered N0 for eligibility purposes. * Patients with micrometastatic nodal involvement (0.2-2 mm) will be considered N1. * Oncotype DX RS (recurrence score) requirements\*: * If node-negative: * Oncotype DX RS must be RS 21-25, or * Oncotype DX RS must be 16-20 and disease must be high clinical risk, defined as: low histologic grade with primary tumor size greater than 3 cm, intermediate histologic grade with primary tumor size greater than 2 cm, or high histologic grade with primary tumor size greater than 1 cm. * If 1-3 nodes involved: * Oncotype DX RS must be less than 26. \* Patients with a "Low Risk" or "MP1" MammaPrint (a genomic test that analyzes the activity of certain genes in early-stage breast cancer) result must have eligibility assessed with an Oncotype DX RS at pre-entry (see Section 3.1). Blocks or unstained slides must be sent to the Genomic Health centralized laboratory for testing at no cost to these patients. If MammaPrint High Risk or MP2, these patients are not eligible. * The tumor must be ER and/or PgR-positive (progesterone receptor) by current ASCO/CAP guidelines based on local testing results. Patients with greater than or equal to 1% ER and/or PgR staining by IHC will be classified as positive. * The tumor must be HER2-negative by current ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines based on local testing results. * The interval between the last surgery for breast cancer (including re-excision of margins) and pre-entry must be no more than 16 weeks. * Short course of endocrine therapy of less than 6 weeks duration before pre-entry is acceptable either as neoadjuvant or adjuvant therapy. An Oncotype DX RS must be performed on core biopsy specimen obtained prior to initiation of neoadjuvant endocrine therapy if received. * Patients with a prior or concurrent non-breast malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. This would include prior cancers treated with curative intent. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Radiation therapy should be used according to standard guidelines; the intended radiation therapy should be declared prior to pre-entry. Exclusion Criteria: * • Definitive clinical or radiologic evidence of metastatic disease. * pT4 (pathological state) tumors, including inflammatory breast cancer. * History of ipsilateral or contralateral invasive breast cancer. (Patients with synchronous and/or previous DCIS or LCIS are eligible.) * If prior ipsilateral DCIS was treated with lumpectomy and XRT (ionizing radiation therapy), a mastectomy must have been performed for the current cancer. * Life expectancy of less than 10 years due to co-morbid conditions in the opinion of the investigator. Known results from most recent lab studies obtained as part of routine care prior to study entry showing ANY of the following values: * ANC (absolute neutrophil count) less than 1200/mm3; * Platelet count less than 100,000/mm3; * Hemoglobin less than 10 g/dL; * Total bilirubin greater than ULN (upper limit of normal) for the lab or greater than 1.5 x ULN for patients who have a bilirubin elevation due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; * AST(aspartate aminotransferase)(SGOT)/ALT (alanine transminase)(SGPT): greater than 3 × institutional ULN; * Renal function of GFR (glomular filtration rate) less than 30 mL/min/1.73m2. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. * Non-epithelial breast malignancies such as sarcoma or lymphoma. * Any treatment with radiation therapy, chemotherapy, or biotherapy administered for the currently diagnosed breast cancer prior to pre-entry. (Patients with prior ET of more than 6 weeks duration for treatment of this cancer are not eligible.) Prior tamoxifen given for breast cancer prevention is allowed. Prior AI or GnRH for fertility preservation is allowed. * Hormonally based contraceptive measures must be discontinued prior to pre-entry (including progestin/progesterone IUDs). * Patients with evidence of chronic hepatitis B virus (HBV) infection are ineligible unless the HBV viral load is undetectable on suppressive therapy. Patients with a history of hepatitis C virus (HCV) infection are ineligible unless they have been treated and cured or have an undetectable HCV viral load if still on active therapy. * Pregnancy or lactation at the time of pre-entry. (Note: Pregnancy testing according to instituti
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this multi-centre, prospective study is to assess the frequency of asymptomatic brain metastasis in patients with stage IIb or III Triple Negative or HER2 positive breast cancer. The main questions it aims to answer are: 1. What proportion of patients with stage IIb or III Triple Negative or HER2 positive breast cancer have asymptomatic brain metastases identified on a screening contrast-enhanced magnetic resonance imaging (MRI) of the brain? 2. How do patients feel about undergoing brain imaging to screen for asymptomatic brain metastasis? 3. What clinical as well as liquid and tissue-based biomarkers are associated with asymptomatic detection of brain metastasis? Participants will undergo brain imaging, provide one blood sample (for analysis of ctDNA), and complete the Testing Morbidities Index (TMI) questionnaire after imaging is done. Procedures may take place either prior to or after completion of (neo)-adjuvant systemic therapy; however, the study interventions must take place within 18 months of initial breast cancer diagnosis.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Brain imaging — Contrast-enahanced Brain Magnetic Resonance Imaging (MRI)
  • Diagnostic Test: Analysis of circulating tumor DNA — Blood draw for analysis of circulating tumor DNA
  • Behavioral: Testing Morbidities Index — Questionnaire regarding the participant's perception of brain imaging.

Primary Outcomes

  • Asymptomatic brain metastasis frequency among HER2+ patients (18 months)
  • Asymptomatic brain metastasis frequency among Triple Negative patients (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-29
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Collaborators: Princess Margaret Hospital, Canada, MOUNT SINAI HOSPITAL, Trillium Health Partners
Principal Investigators:
  • Katarzyna Jerzak, MD, M.Sc (PRINCIPAL_INVESTIGATOR) - Sunnybrook Health Sciences Centre
Contact Information
Study Contact:
Katarzyna Jerzak, MD, M.Sc
416-480-6100
katarzyna.jerzak@sunnybrook.ca
Katarzyna Jerzak, MD M.Sc
416-480-6100
katarzyna.jerzak@sunnybrook.ca
Sunnybrook Health Science Centre
Interventions
  • Diagnostic Test: Brain imaging — Contrast-enahanced Brain Magnetic Resonance Imaging (MRI)
  • Diagnostic Test: Analysis of circulating tumor DNA — Blood draw for analysis of circulating tumor DNA
  • Behavioral: Testing Morbidities Index — Questionnaire regarding the participant's perception of brain imaging.
Study Locations (1 sites)
Sunnybrook Health Science Centre, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria: 1. Age \> 18. 2. Triple Negative OR HER2+ breast cancer (as per 2018 ASCO/CAP guidelines). 3. Stage IIb or III disease. 4. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may participate. 5. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Creatinine clearance \<30 mL/min using the Cockcroft-Gault equation (in accordance with the product monograph for Gadavist IV contrast. 2. Pregnant women are not permitted to participate given that the safety of IV contrast is unknown in this population. 3. Patients with central nervous system symptoms that are concerning for brain metastases that would otherwise be referred for brain imaging.
Conditions Breast Cancer
Phase NA
Enrollment 2706
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Nanomechanical Phenotype Test — The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.

Primary Outcomes

  • ARTIDIS as a sensitive diagnostic tool (Read-out on day 30)
  • ARTIDIS as a specific diagnostic tool (Read-out on day 30)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-02
Completion: 2035-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2706 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ARTIDIS AG
Principal Investigators:
  • Alastair Thompson, MD (PRINCIPAL_INVESTIGATOR) - Baylor College of Medicine
Contact Information
Study Contact:
Julia Ortega, DMSc, MHS, PA
2404980176
julia.ortega@artidis.com
Marko Loparic, MD,PhD
+41 61 633 29 95
Marko.Loparic@artidis.com
Research Manager
214-645-1568
Claire.Starcke@UTSouthwestern.edu
University of Texas Southwestern Medical Center
Interventions
  • Diagnostic Test: Nanomechanical Phenotype Test — The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
Study Locations (6 sites)
University of Texas Southwestern Medical Center, Dallas, Texas 75390-9020 United States
Baylor College of Medicine, Houston, Texas 77030 United States
MD Anderson Cancer Clinic - Mays Clinic, Houston, Texas 77030 United States
University of Washington, Seattle, Washington 98195 United States
Hospital Universitario Vall d'Hebron, Barcelona, Barcelona 08035 Spain
Claraspital, Basel, Basel CH-4058 Switzerland
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥ 18 years * Ability to understand and the willingness to sign a written informed consent. * Indication for breast biopsy for diagnostic purposes * ECOG performance status of 0 to 3. Exclusion Criteria: * Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.
Conditions Breast Cancer (Early Breast Cancer), Car...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care. The main questions it aims to answer are: Can changes in Global Longitudinal Strain (GLS) on echocardiography detect early cardiac dysfunction before a drop in left ventricular ejection fraction (LVEF) becomes apparent? Are changes in circulating microRNA levels in the blood associated with early cardiac dysfunction during cancer treatment? Does cardiac dysfunction occur more frequently with anthracycline-containing chemotherapy compared to anthracycline-free regimens? Participants already receiving standard chemotherapy and/or anti-HER2 therapy as part of their routine cancer care will undergo echocardiography (LVEF and GLS), provide blood samples for microRNA analysis, and complete quality of life questionnaires at four time points: before treatment (baseline), and at 3, 6, and 12 months after starting treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence of cancer therapy-related cardiac dysfunction (CTRCD) (From baseline through Month 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-11
Completion: 2028-03-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fatih GURLER
Principal Investigators:
  • Fatih Gürler (PRINCIPAL_INVESTIGATOR) - Gazi University
Contact Information
Study Contact:
Sıla Soylu Koçoğlu, MD
+905012735223
drsilasoylu@gmail.com
Fatih Gürler, MD
+905325495597
drfatihgurler@gmail.com
Sıla Soylu Koçoğlu, MD
+905012735223
drsilasoylu@gmail.com
Gazi University Faculty of Medicine
Interventions
N/A
Study Locations (1 sites)
Gazi University Faculty of Medicine, Ankara, Ankara 06560 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of breast cancer * Stage I, II, or III disease * Planned neoadjuvant or adjuvant chemotherapy and/or HER2-targeted systemic therapy * Baseline transthoracic echocardiographic left ventricular ejection fraction (LVEF) ≥ 50% * Age ≥ 18 years * Able and willing to provide written informed consent Exclusion Criteria: * Metastatic (Stage IV) breast cancer * Pre-existing heart failure or clinically significant cardiac disease * Prior exposure to chemotherapy or other cardiotoxic systemic therapy * Concurrent active malignancy other than breast cancer * Inability or unwillingness to comply with the planned follow-up and assessment schedule
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 55
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies whether time restricted eating (TRE) works to improve outcomes in patients with stage I-III breast cancer receiving chemotherapy before surgery (neoadjuvant) with a body mass index (BMI) 25-40. TRE has been shown to elicit similar metabolic changes as calorie restriction such as reduction in blood glucose levels, improved insulin sensitivity, and reduction of tumor cell growth. TRE may improve outcomes in patients with breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Short-Term Fasting — Undergo TRE
  • Drug: Chemotherapy — Receive standard of care neoadjuvant chemotherapy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Proportion of patients who can adhere to time restricted eating (TRE) >= 70% of days (While undergoing neoadjuvant chemotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-07-28
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Principal Investigators:
  • Maysa Abu-Khalaf, MD, MBA (PRINCIPAL_INVESTIGATOR) - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Contact Information
Study Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu
Maysa Abu-Khalaf, MD
215-955-8874
Jefferson Cherry Hill Hospital
Maysa Abu-Khalaf, MD
215-955-8874
Sidney Kimmel Cancer Center Washington Township, , NJ USA
Interventions
  • Other: Short-Term Fasting — Undergo TRE
  • Drug: Chemotherapy — Receive standard of care neoadjuvant chemotherapy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (5 sites)
Jefferson Cherry Hill Hospital, Cherry Hill, New Jersey 08002 United States
Sidney Kimmel Cancer Center Washington Township, , NJ USA, Sewell, New Jersey 08080 United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107 United States
Jefferson Torresdale Hospital, Philadelphia, Pennsylvania 19114 United States
Asplundh Cancer Pavilion, Willow Grove, Pennsylvania 19090 United States
Eligibility Criteria
INCLUSION CRITERIA: * Patient must be \>= 18 years of age at time of consent and must be able to understand and provide informed consent * BMI 25-40 at time of enrollment * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Patient must have a recent diagnosis of histologically confirmed primary invasive breast carcinoma \* Oligometastatic disease is allowed if treating physician recommends standard neoadjuvant chemotherapy * Patients must have clinical stage I-III (utilizing tumor, node, metastasis \[TNM\] criterion) at diagnosis * Clinical T size must be \>= 1.5 cm if there is no radiographic or clinical evidence of axillary lymph node involvement. Any size tumor is allowed if axillary lymph nodes appear to be involved * Patient must be willing and able (have no contraindication) to receive recommended standard neoadjuvant therapy consisting of at least 16 weeks of planned neoadjuvant chemotherapy * Patients must have organ and marrow function adequate for initiating neoadjuvant chemotherapy as determined by their treating physician * Patient must be willing and able (have no contraindication) to participate in TRE consisting of 16 weeks * Women of childbearing potential and sexually active males must use accepted and effective method(s) of contraception or abstain from sexual intercourse for the duration of their participation in the study and for 6 months after the last study intervention * Patient must have a personal email address, an internet-capable device, and the ability/ willingness to read and reply to email every day for the duration of the study EXCLUSION CRITERIA: * Clinical T4 and/or N3 disease, including inflammatory breast cancer * Any prior treatment for the current breast cancer diagnosis, including surgery, chemotherapy, radiation, or experimental therapy * Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. Patients must also not expect to conceive from the time of registration, while on study treatment, and until at least 6 months after the last study intervention * Patients with type 1 diabetes, or type 2 diabetes treated with insulin * Patients with a history of eating disorder * Patients who work on a rotating shift schedule * Patients must not have impaired decision-making capacity * Patients who are not English speaking as study staff is only able to provide the study intervention measurement tool * Patients that are \> 2 weeks into starting neoadjuvant chemotherapy regimen
Conditions Pediatric Obesity, Type 2 Diabetes
Phase NA
Enrollment 73
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicentre, single-arm, feasibility study in adolescents with T2DM and obesity to investigate the recruitment and retention rates to a study using Low Energy Diets(LED). It will also provide estimates of weight loss needed to bring about remission to inform a larger randomised study. In addition a subgroup of participants and their parents/carers undertaking a period of LED will be interviewed to understand the participants experience of taking part. Two further groups will also be interviewed: participants and their parents/carers who have declined to take part in the LED to understand their motivations and barriers and healthcare practitioners who have participated in conducting the trial to understand their experience of the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Low-energy diet — For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
  • Other: Qualitive interview - LED participants — Semi-structured interviews with 10 of the LED participants and their relative/carer.
  • Other: Qualitive interview - Participants declining LED — Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
  • Other: Qualitive interview - Health Care Professionals (HCPs) — Semi-structured interviews with 10 HCPs involved in delivery of the trial.

Primary Outcomes

  • Proportion of potential participants that can be recruited to an LED intervention (12 months)
  • Retention rate measured by by data availability for participant height. (12 months)
  • Retention rate measured by by data availability for participant weight. (12 months)
  • Retention rate measured by by data availability for participant HbA1C. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-30
Completion: 2028-05-29
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 73 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nottingham University Hospitals NHS Trust
Collaborators: Diabetes UK
Contact Information
Study Contact:
Pooja Sachdev, MD
0115 924 9924
pooja.sachdev@nhs.net
Gemma Boam, PhD
gemma.boam@nhs.net
Pooja Sachdev, MD
0115 924 9924
pooja.sachdev@nhs.net
Nottingham University Hospital NHS Trust
Interventions
  • Dietary Supplement: Low-energy diet — For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
  • Other: Qualitive interview - LED participants — Semi-structured interviews with 10 of the LED participants and their relative/carer.
  • Other: Qualitive interview - Participants declining LED — Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
  • Other: Qualitive interview - Health Care Professionals (HCPs) — Semi-structured interviews with 10 HCPs involved in delivery of the trial.
Study Locations (1 sites)
Nottingham University Hospital NHS Trust, Nottingham, NG7 2UH United Kingdom
Eligibility Criteria
Inclusion criteria LED intervention * Diagnosis of T2DM (defined as an HbA1C ≥48mmol/mol, in the absence of features of type 1 or monogenic/syndromic diabetes). * Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤ 80 mmol/mol. To allow for the day-to-day variation in HbA1C and differences between point of care laboratory tests, -2 or +2 mmol/mol in the HbA1C result will be allowed in the current criteria if one of them is between or equal to 42-80mmol/mol. * Aged 12 to 17 years old. * BMI ≥981st centile (+2 SD) for age and sex (UK90 growth reference data). * Informed consent: * Received from the young person (age 16-17) OR * Received from young person's parent/carer, with patient assent (age 12-15). * Willing to engage in and commit to low energy diet, FR and weight management phases including follow-up and attending study visits. LED Intervention Interviews The same interview inclusion criteria for LED intervention, with the following additional requirements: Patients: * Informed consent: * Received from the young person (age 16-17) OR * Received from young person's parent/carer, with patient assent (age 12-15). * Willing to take part in a qualitative interview alongside a parent/carer. Relative/Carer: * A relative/carer for a young person meeting the above LED participant eligibility criteria. * Informed consent from the relative/carer to participate in the interview. * Willing to take part in a qualitative interview alongside the young person. Non-LED Qualitative Interview only participants * Diagnosis of T2DM (defined as an HbA1C ≥48mmol/mol, in the absence of features of type 1 or monogenic/syndromic diabetes). * Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤80 mmol/mol. * Aged 12 to 17 years old. * BMI ≥91st centile (+2 SD) for age and sex (UK90 growth reference data). * Informed consent: * Received from the young person (age 16-17) OR * Received from young person's parent/carer, with patient assent (age 12-15). * Willing to take part in a qualitative interview alongside a parent/carer only. HCPs * Registered HCP. * Experience of delivering this trial to the adolescents. * Willing to take part in a qualitative interview about undertaking motivational interviewing training and conducting/delivering the LED intervention study. Exclusion criteria LED intervention * HbA1C greater than 82mmol/mol (to allow for the variation in HbA1c differences). * Presence of diabetes-related autoantibodies, as per local centre guidelines. * Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome. * Secondary diabetes (post bone marrow transplant/chemotherapy). * Significant psychiatric co-morbidity. * Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10). * Any other condition which, in the opinion of the study investigator, would make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt). * Participation in another interventional trial within 6 months. * Informed consent and/or assent not received. * Pre-existing retinopathy. * Dietary avoidance (including, but not limited to, due to allergies, intolerances, religious reasons and lifestyle choices) to any ingredients in the meal replacement products, including lactose. * Previous scoliosis repair. Non-LED Qualitative Interview only participants * HbA1C greater than 80mmol/mol. * Presence of diabetes-related autoantibodies, as per local centre guidelines. * Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome. * Secondary diabetes (post bone marrow transplant/chemotherapy). * Significant psychiatric co-morbidity. * Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10). * Any other condition which, in the opinion of the study investigator, would either make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt). * Participation in another interventional trial within 6 months. * Informed consent and/or assent not received. * Pre-existing retinopathy. * Dietary avoidance (including, but not limited to, due to allergies, intolerances, religious reasons and lifestyle choices) to any ingredients in the meal replacement products, including lactose. * Previous scoliosis repair. HCPs • None.
Conditions Type 2 Diabetes
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved glycemic control in 15 adolescents with T2DM identified in Aim 1 as having \<8 hr sleep/evening. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Loss frame sleep extension intervention — Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.

Primary Outcomes

  • Sleep duration (for Aim 2) (13 weeks)
  • Hemoglobin A1c (for Aim 1) (baseline)
  • BMI (for Aim 1) (baseline)
  • Qualitative data from focus group (baseline at focus group)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-09-16
Completion: 2028-07-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital of Philadelphia
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Talia A Hitt, MD/MPH (STUDY_DIRECTOR) - Children's Hospital of Philadelphia
Contact Information
Study Contact:
Talia Hitt, MD/MPH
215-590-3174
hittt@chop.edu
Beth Schwartzman
215-590-3174
schwartzmann@chop.edu
Interventions
  • Behavioral: Loss frame sleep extension intervention — Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
Study Locations (1 sites)
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: Aim 1 for child: 1. Subjects age 12-20 2. Diagnosed with T2DM by standard laboratory criteria without pancreatic autoimmunity 3. Low probability of obstructive sleep apnea (OSA) assessed via validated sleep survey 4. Subjects will be included if they are taking T2DM treatments (i.e., diet modification, Metformin and/or insulin) 5. Parental/guardian permission and child assent Aim 1 for parent: 1\. Parent or legal guardian of child that meets inclusion criteria for Aim 1. Aim 2 for child: 1. Completed Aim 1 evaluation 2. Average sleep duration \< 8 hours per night as determined by actigraphy in Aim 1 3. HbA1c ≤ 10% as HbA1c \>10 correlates to poor adherence 4. Adherence \> 80% Focus group for child: 1. Subjects aged 12-20 2. Diagnosed with type 2 diabetes without pancreatic autoimmunity Exclusion Criteria: Aim 1 for child: 1. Non-English speaking subject (as questionnaires used are validated in English) 2. Institutionalized patients as sleep duration will not be of their own accord, and therefore is not generalizable to the rest of the adolescent T2DM population. 3. Patients with other forms of Diabetes Mellitus (e.g. Type 1 Diabetes) 4. Behavioral disorders that may affect data collection (e.g. autism spectrum disorder) will be determined on a case-by-case basis. These include patients that are unable to answer questionnaires on their own, participate in a sleep diary, wear devices and/or understand incentives. 5. Oral or IV steroid treatment within the past month 6. Females with known pregnancies as these patients will not be generalizable to the rest of the adolescent T2DM population and pregnancy may alter sleep duration. 7. Subjects with known hyperthyroidism, pain syndrome, or serious medical condition that can affect sleep. 8. Subjects with hemoglobinopathies that affect hemoglobin A1c measurement. 9. Unable to obtain point-of-care hemoglobin A1c in clinic on date of recruitment 10. Known diagnosis of obstructive sleep apnea or other sleep disorder Aim 1 for Parent: 1. Non-English speaking subject (as questionnaires used are validated in English) 2. Parent/guardians with cognitive disorders that may affect data collection (determined on a case-by-case basis) Aim 2 for child: 1\. Do not own a smart phone or tablet Focus group for child: 1. Non-English speaking subject (as focus group will be conducted in English) 2. Lack of access to a computer, tablet or smartphone that can accommodate participation in video conferencing